#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)June 04, 2023

 

 #### Chicago, USA

 

 

 

[Read the press release](/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups "Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups")

[Download the presentation (PDF 1.2 MB)](/sites/novartis_com/files/2023-06-novartis-asco-presentation.pdf "2023-06-novartis-asco-presentation.pdf")